Dr. Witteles is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
Falk Cvrc, Stanford University Hospital
Palo Alto, CA 94305Phone+1 650-498-4343- Is this information wrong?
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 2004 - 2007
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2000 - 2003
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000
Certifications & Licensure
- CA State Medical License 2001 - 2025
- OR State Medical License 2020 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Most Compassionate Doctor American Registry
- Fellow (FACC) American College of Cardiology
Clinical Trials
- BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS) Start of enrollment: 2004 Mar 01
- Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure Start of enrollment: 2008 Apr 01
- Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation Start of enrollment: 2021 Apr 01
Publications & Presentations
PubMed
- Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation.Melesio, J., Bonilauri, B., Li, A., Pang, P., Liao, R., Witteles, R., Wu, J., Sallam, K.> ;Stem Cell Research. 2024 Feb 1
- 1 citationsTafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.Pablo Garcia-Pavia, Marla B Sultan, Balarama Gundapaneni, Yoshiki Sekijima, Federico Perfetto, Mazen Hanna, Ronald Witteles> ;JACC. Heart Failure. 2024 Jan 1
- 1 citationsGeneration of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation.Bernardo Bonilauri, Hye Sook Shin, Min Htet, Christopher D Yan, Ronald M Witteles, Karim Sallam, Joseph C Wu> ;Stem Cell Research. 2023 Oct 1
- Join now to see all
Abstracts/Posters
- Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL AmyloidosisRonald Witteles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep ResponsesRonald Witteles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Authored Content
- Summary of Clinical Trials for the Prevention and Treatment of Cardiomyopathy Related to Anthracyclines and HER2-Targeted AgentsJuly 2020
- Summary of Clinical Trials for the Prevention and Treatment of Cardiomyopathy Related to Anthracyclines and HER2-Targeted AgentsJuly 2020
Press Mentions
- Atorvastatin Cut Anthracycline Cardiac Dysfunction in LymphomaMarch 4th, 2023
- Global Cardio-Oncology Viewpoints ‘Contextualize’ ESC GuidelinesDecember 12th, 2022
- COVID-19 Vaccine Rollout Plagued by Protests, Failed Technology and Front-Line Workers Missing OutDecember 22nd, 2020
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: